Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Phase 2 Interventional Results available

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

NCT02431468
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bryostatin 1, Placebo
Drug · Other
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Phoenix, Arizona • Costa Mesa, California • Los Alamitos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 30, 2026, 10:36 PM EDT
Terminated Phase 3 Interventional

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

NCT01168791
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Palifosfamide-Tris, doxorubicin, Placebo
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alcohol Self Administration Laboratory

NCT00398918
View directory record Official record
Conditions
Alcoholism
Interventions
zonisamide, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 30, 2026, 10:36 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

NCT05540860
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
4 Years to 9 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 30, 2026, 10:36 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults

NCT07226882
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 44 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
6
States / cities
Warren Township, New Jersey • Cortland, New York • Horseheads, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

NCT02091882
View directory record Official record
Conditions
Device Latency
Interventions
Placebo, Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
Drug · Combination Product
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

NCT03877224
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 150 Years
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
25
States / cities
Alexander City, Alabama • Fort Payne, Alabama • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Phenytoin for Memory Impairment Secondary to Megestrol

NCT02595723
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Phenytoin 200 mg capsule, Megestrol 800 mg liquid, Phenytoin-matched Placebo capsule, Megestrol-matched liquid Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 30, 2026, 10:36 PM EDT
Recruiting Phase 3 Interventional

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

NCT07339423
View directory record Official record
Conditions
Obesity
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
22
States / cities
Miramar, Florida • Orlando, Florida • Conyers, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

NCT01135680
View directory record Official record
Conditions
Drug Toxicity
Interventions
HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

NCT00401830
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
25
States / cities
Litchfield Park, Arizona • Santa Ana, California • Walnut Creek, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 30, 2026, 10:36 PM EDT
Terminated Phase 3 Interventional Results available

A Study of PRN1008 in Patients With Pemphigus

NCT03762265
View directory record Official record
Conditions
Pemphigus
Interventions
Rilzabrutinib, Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Boca Raton, Florida • Coral Gables, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 30, 2026, 10:36 PM EDT
Terminated Phase 3 Interventional Results available

An Efficacy and Safety Study of Ravulizumab in ALS Participants

NCT04248465
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
Placebo, Ravulizumab
Drug · Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 30, 2026, 10:36 PM EDT
Recruiting Phase 2 Interventional

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

NCT06949800
View directory record Official record
Conditions
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions
EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

NCT00619892
View directory record Official record
Conditions
Panic Disorder
Interventions
quetiapine XR, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

NCT04470544
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome
Interventions
Camostat Mesilate, Standard of Care
Drug · Other
Lead sponsor
Alan Bryce
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Scottsdale, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Trial to Evaluate Magtein in Older Adults

NCT02363634
View directory record Official record
Conditions
Mood, Anxiety
Interventions
magnesium threonate
Dietary Supplement
Lead sponsor
Miami Research Associates
Network
Eligibility
45 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of Various Cannabinoids on Sleep Quality

NCT07769164
View directory record Official record
Conditions
Sleep Disturbance, Sleep Quality
Interventions
2 mg THC + 2 mg CBN + 2 mg CBG + 10 mg CBD + 1 mg Melatonin, 10 mg THC + 5 mg CBN + 5 mg CBG + 20 mg CBD, 10 mg THC + 20 mg CBN + 5 mg CBG, Stay Asleep Placebo, Fast Asleep Placebo
Dietary Supplement
Lead sponsor
Cannabis Science Innovations, LLC
Industry
Eligibility
21 Years to 55 Years
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of GH and Lirglutide on AgRP

NCT05681299
View directory record Official record
Conditions
Healthy, Growth Hormone Deficiency
Interventions
growth hormone and lirglutide, growth hormone, liraglutide, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

NCT01030432
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-650032, Placebo, Peginterferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 30, 2026, 10:36 PM EDT
Terminated Phase 2 Interventional Results available

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

NCT04442230
View directory record Official record
Conditions
Coronavirus Infection
Interventions
NasoVAX, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Miami, Florida • Morrow, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 30, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Genioglossus Muscle Training for Snoring and Obstructive Sleep Apnea

NCT02834767
View directory record Official record
Conditions
Snoring, Sleep Apnea, Obstructive
Interventions
Genioglossis Strength Trainer, Placebo Genioglossis Strength Trainer
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 30, 2026, 10:36 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 30, 2026, 10:36 PM EDT
Completed No phase listed Observational

Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density

NCT00418236
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 63 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
San Diego, California • Upland, California • Meridian, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 30, 2026, 10:36 PM EDT